Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts’ perspective

References

• Nappi RE, Kroll R, Siddiqui E, et al. Global cross-sectional survey of women with vasomotor symptoms associated with menopause: prevalence and quality of life burden. Menopause. 2021;28:875–882.
   PubMed Web of Science ®Google Scholar
• Panay N, Palacios S, Davison S, et al. Women’s perception of the menopause transition: a multinational, prospective, community-based survey – Gynecological and reproductive endocrinology & metabolism. Gynaecol Reprod Endocrinol Metab. 2021;2:178–183.
   Google Scholar
• Palacios S, Stevenson JC, Schaudig K, et al. Hormone therapy for first-line management of menopausal symptoms: practical recommendations. Women’s Heal. 2019;15:1745506519864009. doi: 10.1177/1745506519864009
   Google Scholar
• Antoine C, Ameye L, Paesmans M, et al. Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. Maturitas. 2016;84:81–88.
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s health initiative randomized controlled trial. JAMA. 2002;288:321–333.
   PubMed Web of Science ®Google Scholar
• Manson JE, Kaunitz AM. Menopause management — getting clinical care back on track. N Engl J Med. 2016;374:803–806.
   PubMed Web of Science ®Google Scholar
• Manson JAE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318:927–938.
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019:394;1159–1168. doi: 10.1016/S0140-6736(19)31709-X
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:3975–4011.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Gass MLS, Manson JE, et al. A decade after the Women’s health initiative - the experts do agree. Fertil Steril. 2012;98:313–314.
   PubMed Web of Science ®Google Scholar
• Olié V, Plu-Bureau G, Conard J, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18:488–493.
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Hall JE, Pinkerton JV, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016;19:313–315.
   PubMed Web of Science ®Google Scholar
• De Villiers TJ, Pines A, Panay N, et al. Updated 2013 International menopause society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16:316–337.
   PubMed Web of Science ®Google Scholar
• Langer RD, Manson JE, Allison MA. Have we come full circle or moved forward? the Women’s health initiative 10 years on. Climacteric. 2012;15:206–212.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016;19:109–150.
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? Osteoporos Int. 2020;31:2271–2286.
   PubMed Web of Science ®Google Scholar
• Yeganeh L, Boyle J, Teede H, et al. Knowledge and attitudes of health professionals regarding menopausal hormone therapies. Climacteric. 2017;20:348–355.
   PubMed Web of Science ®Google Scholar
• Gompel A. Progesterone and endometrial cancer. Best Pract Res Clin Obstet Gynaecol. 2020;69:95–107. doi: 10.1016/j.bpobgyn.2020.05.003
   PubMed Web of Science ®Google Scholar
• Santen RJ, Heitjan DF, Gompel A, et al. Underlying breast cancer risk and menopausal hormone therapy. J Clin Endocrinol Metab. 2020;105(6):e2299–e2307.
   Web of Science ®Google Scholar
• Boardman HMP, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;2015(3):CD002229. doi: 10.1002/14651858.CD002229.pub4
   PubMed Web of Science ®Google Scholar
• Parish SJ, Nappi RE, Kingsberg S. Perspectives on counseling patients about menopausal hormone therapy: strategies in a complex data environment. Menopause. 2018;25:937–949.
   PubMed Web of Science ®Google Scholar
• El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142:e506–e532.
   PubMed Web of Science ®Google Scholar
• Thurston RC, Wu M, Chang Y-F, et al. Menopausal vasomotor symptoms and white matter hyperintensities in midlife women. Neurology. 2023;100:e133–e141.
   PubMed Web of Science ®Google Scholar
• Crandall CJ, Aragaki A, Cauley JA, et al. Associations of menopausal vasomotor symptoms with fracture incidence. J Clin Endocrinol Metab. 2015;100:524–534.
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Vandromme J. Attitudes to the prescription of menopause hormone therapy for vasomotor symptoms and osteoporosis for patients of different ages: a survey of gynecologists in Belgium. Maturitas. 2019;128:60–63.
   PubMed Web of Science ®Google Scholar
• Stute P, Cano A, Thurston RC, et al. Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States. Maturitas. 2022;164:38–45.
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;CD002978. doi: 10.1002/14651858.CD002978.pub2
   Google Scholar
• Stute P, Eversheim H, Ortius-Lechner D, et al. Care reality of menopausal women in Germany: healthcare research using quantitative (SHI claims data) and qualitative (survey) data collection. Arch Gynecol Obstet. 2022;306:513–521.
   PubMed Web of Science ®Google Scholar
• Tepper PG, Brooks MM, Randolph JFJ, et al. Characterizing the trajectories of vasomotor symptoms across the menopausal transition. Menopause. 2016;23:1067–1074.
   PubMed Web of Science ®Google Scholar
• Chen Z, Bassford T, Green SB, et al. Postmenopausal hormone therapy and body composition–a substudy of the estrogen plus progestin trial of the Women’s health initiative. Am J Clin Nutr. 2005;82:651–656.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010;67:233–238.
   PubMed Web of Science ®Google Scholar
• Hickey M, Moss KM, Krejany EO, et al. What h Serge s after menopause? (WHAM): a prospective controlled study of sleep quality up to 12 months after premenopausal risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2021;162:447–453.
   PubMed Web of Science ®Google Scholar
• Secoșan C, Balint O, Pirtea L, et al. Surgically induced menopause—A practical review of literature. Med (Kaunas). 2019;55(8):482. doi: 10.3390/medicina55080482
   PubMed Web of Science ®Google Scholar
• Mcintosh J, Blalock S. Effects of media coverage of Women’s health initiative study on attitudes and behavior of women receiving hormone replacement therapy. Am J Health Syst Pharm. 2005;62:69–74.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Graham S, Clerinx C, et al. Behaviours and attitudes influencing treatment decisions for menopausal symptoms in five European countries. Post Reprod Heal. 2016;22:112–122.
   PubMedGoogle Scholar
• Herbert D, Bell RJ, Young K, et al. Australian women’s understanding of menopause and its consequences: a qualitative study. Climacteric. 2020;23:622–628.
   PubMed Web of Science ®Google Scholar
• Depypere H, Pintiaux A, Desreux J, et al. Coping with menopausal symptoms: an internet survey of Belgian postmenopausal women. Maturitas. 2016;90:24–30.
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115:840–845.
   PubMed Web of Science ®Google Scholar
• Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010;30:340–345.
   PubMed Web of Science ®Google Scholar
• Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10:2277–2286.
   PubMed Web of Science ®Google Scholar
• Posadzki P, Lee MS, Moon T, et al. Prevalence of complementary and alternative medicine (CAM) use by menopausal women: a systematic review of surveys. Maturitas. 2013;75:34–43.
   PubMed Web of Science ®Google Scholar
• Hillman S, Shantikumar S, Ridha A, et al. Socioeconomic status and HRT prescribing: a study of practice-level data in England. Br J Gen Pract. 2020;70:E772–E777.
   PubMed Web of Science ®Google Scholar
• Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging Methods-Scientists from five countries and multiple disciplines evaluated data from cohort studies of midlife women and in. Menopause. 2012;19:387–395.
   PubMed Web of Science ®Google Scholar
• Banks E, Beral V, Bull D, et al. Breast cancer and hormone-replacement therapy in the million women study. Lancet. 2003;362:419–427.
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases. BMJ. 2020;371:m3873.
   PubMed Web of Science ®Google Scholar
• Cold S, Cold F, Jensen M-B, et al. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. JNCI J Natl Cancer Inst. 2022;114(10):1347–1354. doi: 10.1093/jnci/djac112
   Web of Science ®Google Scholar
• Tempfer CB, Hilal Z, Kern P, et al. Menopausal hormone therapy and risk of endometrial cancer: a systematic review. Cancers (Basel). 2020;12(8):2195. Article 2195. doi: 10.3390/cancers12082195
   PubMed Web of Science ®Google Scholar
• Labadie JD, Harrison TA, Banbury B, et al. Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes and tumor location. JNCI Cancer Spectr. 2020;4:kaa042.
   Web of Science ®Google Scholar
• Paganini-Hill A, Corrada MM, Kawas CH. Increased longevity in older users of postmenopausal estrogen therapy: the leisure world cohort study. Menopause. 2018;25:1256–1261.
   PubMed Web of Science ®Google Scholar
• Pinkerton JAV, Aguirre FS, Blake J, et al. The 2017 hormone therapy position statement of the North American menopause society. Menopause. 2017;24:728–753.
   PubMed Web of Science ®Google Scholar